TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03248947
Drug: buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
Study: NCT00943982
Drug: Interferon Gamma 1-b
Normalized name: Interferon gamma 1-b
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01326117
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days of Cialis for Daily Use (5mg)
Study: NCT01552187
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5 mg BID or colchicine 0.5mg (\<70kg) 48 to 72 hours before surgery till 1 months after surgery
Study: NCT01464788
Drug: Low Dose Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
Study: NCT01464788
Drug: High Dose Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
Study: NCT01464788
Drug: rt-PA (alteplase)
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
Study: NCT03069482
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
Study: NCT03069482
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
Study: NCT01114854
Drug: Topiramate IR
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01114854
Drug: Topiramate ER
Normalized name: Topiramate ER
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01811355
Drug: Mexiletine
Normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium channel blocker
Study: NCT00311558
Drug: sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSG \& IFN
Study: NCT02513784
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
Study: NCT01924052
Drug: CGRP
Normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin-gene-related-peptide (CGRP)
Study: NCT02393573
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will take metformin for two weeks before Surgery and 2 days after the surgery
Study: NCT01797965
Drug: BIIB019 (Daclizumab)
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
Study: NCT03298191
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Those women will be given Magnesium Sulfate for tocolysis
Study: NCT03298191
Drug: Ritodrine
Normalized name: Ritodrine
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Those women will be given Ritodrine for tocolysis
Study: NCT00639717
Drug: tacrolimus (standard GVHD prophylaxis)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
Study: NCT00639717
Drug: mycophenolate (standard GVHD prophylaxis)
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
Study: NCT00639717
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
Study: NCT00639717
Drug: methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped.
Study: NCT01785810
Drug: Maraviroc 300 mg
Normalized name: maraviroc 300 MG
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
Study: NCT02559154
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02559154
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03641482
Drug: NBF
Normalized name: SODIUM MONOFLUOROPHOSPHATE 0.4 g in 30 g DENTAL GEL [NBF Gingival]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
Study: NCT01704417
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
Study: NCT01704417
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
Study: NCT04222348
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 850-2550 mg every 24h.
Study: NCT04222348
Drug: Insulin Detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
Study: NCT02559154
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03885089
Drug: Infliximab [infliximab biosimilar 3]
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: \<Psoriasis\> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
Study: NCT00443235
Drug: Melphalan/Prednisone/Velcade
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)
Study: NCT00443235
Drug: Thalidomide/Prednisone/Velcade
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)
Study: NCT01066195
Drug: iressa
Normalized name: Iressa
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iressa 250mg per day every day
Study: NCT01066195
Drug: alimta
Normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: alimta 500mg/m2 every 3 weeks
Study: NCT02705508
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
Study: NCT02705508
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
Study: NCT02705508
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2500U/m2 im on day 1 of each 21 day cycle.
Study: NCT01486784
Drug: Birinapant
Normalized name: Birinapant
DrugBank: Birinapant (DB11782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
Study: NCT04802980
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin is an anti-tumor drug
Study: NCT04802980
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is an anti-tumor drug
Study: NCT04802980
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is an anti-tumor drug
Study: NCT04802980
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is an anti-tumor drug
Study: NCT04802980
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is an anti-tumor drug
Study: NCT00498108
Drug: Rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03220711
Drug: Fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescent dye used for imaging contrast only.
Study: NCT03054948
Drug: SMOFLipid
Normalized name: Smoflipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
Study: NCT02687230
Drug: MVT-2163
Normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MVT-2163 is administered intravenously as a PET imaging agent
Study: NCT02687230
Drug: MVT-5873
Normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
Study: NCT03523221
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
Study: NCT01887587
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01887587
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02941913
Drug: palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
Study: NCT02017236
Drug: Volitinib
Normalized name: Volitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg Volitinib ,single dose,oral
Study: NCT01711684
Drug: Diphenylcyclopropenone (DPCP)
Normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of study drug
Study: NCT00473837
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
Study: NCT03850782
Drug: Bimatoprost (SR)
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR.
Study: NCT01397448
Drug: E3810
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
Study: NCT01397448
Drug: E3810
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
Study: NCT01397448
Drug: Teprenone
Normalized name: teprenone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
Study: NCT01016691
Drug: High Dose Drug Device
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: device inserted for 4 days
Study: NCT01016691
Drug: Low Dose Drug Device
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: device inserted for 4 days
Study: NCT01016691
Drug: bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one drop in each eye on one day only
Study: NCT00488592
Drug: GM-CSF (Sargramostim)
Normalized name: axatilimab-csfr
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
Study: NCT05414305
Drug: Heparin & Alkalinized Lidocaine Bladder Instillation
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
Study: NCT01808690
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04095754
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
Study: NCT03280641
Drug: Dabigatran Etexilate 110mg
Normalized name: DABIGATRAN ETEXILATE 110MG CAP,ORAL
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran Etexilate 110mg, BID
Study: NCT03280641
Drug: Warfarin Sodium
Normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target INR:1.6-3.0
Study: NCT02121756
Drug: Dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
Study: NCT02121756
Drug: Placebo, then Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
Study: NCT02896712
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
Study: NCT00292448
Drug: Tiotropium (Spiriva) inhalation capsule 18 ug
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01755468
Drug: Intermittent insulin therapy
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00881855
Drug: Cefprozil 500 mg Tablets (Sandoz, GmbH)
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00881855
Drug: Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
Normalized name: cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00138424
Drug: Cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
Study: NCT00208741
Drug: Gabitril
Normalized name: Gabitril
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04311177
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan; 25 mg daily; oral administration
Study: NCT02517151
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004363
Drug: chlorpropamide
Normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004363
Drug: desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00062699
Drug: Zemplar (paricalcitol injection)
Normalized name: paricalcitol Injection [Zemplar]
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00062699
Drug: Calcijex
Normalized name: Calcijex
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03280342
Drug: XR-TPM (Trokendi XR)
Normalized name: TPM
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: XR-TPM (Trokendi XR)
Study: NCT00450801
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 IV, Days 1 of all cycles
Study: NCT02193815
Drug: 2%Tofacitinib Ointment
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily Dosage: approximately 4 mg tofacitinib
Study: NCT02193815
Drug: Daivonex
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
Study: NCT02193815
Drug: Daivonex Ointment
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
Study: NCT00930605
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
Study: NCT00278772
Drug: Divalproex
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, 15mg/kg/day - 30mg/kg/day